Ring Carbon Of One Of The Five-membered Hetero Rings Is Bonded Directly To Ring Carbon Of The Other (e.g., Indigo Dyes, Etc.) Patents (Class 548/457)
  • Patent number: 11384245
    Abstract: Aqueous leucoindigo solution comprising an aromatic amine, in particular aniline or aniline and N-methylaniline, wherein the concentration of the aromatic amine is below 200 ppm, wherein the leucoindigo salt in the solution is in the form of a mixed sodium and potassium salt, wherein the molar ratio of sodium to potassium is in the range of from above 3:1 to 10:1, preferably wherein the concentration of the salt is in the range of from above 25 to 45% by weight, based on the total weight of the solution.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: July 12, 2022
    Assignee: Archroma IP GmbH
    Inventors: Erwin Lucic, Jorg Hubner
  • Patent number: 10285979
    Abstract: A breast cancer therapeutic agent containing 5?-hydroxy-5-nitro-indirubin-3?-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5?-hydroxy-5-nitro-indirubin-3?-oxime as cyclin-dependent kinase (CDK) inhibitor, wherein said breast cancer is triple negative breast cancer (TNBC) and/or an estrogen receptor (ER) positive breast cancer including the tamoxifen-resistant estrogen receptor (ER) positive breast cancer has been disclosed.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: May 14, 2019
    Assignee: ANYGEN CO., LTD.
    Inventors: Jae il Kim, Seon-Myung Kim, San Ho Kim, Moon Young Park
  • Patent number: 8859783
    Abstract: The present invention relates to an indirubin-3?-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3?-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 14, 2014
    Assignee: Anygen Co., Ltd.
    Inventors: Yong-Chul Kim, Jae-Il Kim, Soo-Ho Ban, Soon-Young Jeong, Soo-Jeong Choi, Jung-Eun Lee
  • Patent number: 8841276
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: September 23, 2014
    Assignees: Emory University, The United States of America as represented by the Department of Veterans Affairs
    Inventor: Jack L. Arbiser
  • Publication number: 20140275168
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Sangkil NAM, Richard JOVE, Leandros SKALTSOUNIS
  • Publication number: 20140200253
    Abstract: An agent for treating malignant tumors based on a new mechanism is provided, which comprises an indirubin derivative represented by formula (1) or a salt thereof: wherein A represents an alkylene group having 1 to 4 carbon atoms, and R1 to R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, or an alkoxy group.
    Type: Application
    Filed: July 5, 2012
    Publication date: July 17, 2014
    Applicant: NIHON UNIVERSITY
    Inventors: Takashi Suzuki, Shinichi Miyairi, Hiroaki Saito, Keiichi Tabata
  • Publication number: 20140184997
    Abstract: Disclosed is a polyimide prepolymer, an alignment film and a method for preparing the same, as well as a liquid display device. The polyimide prepolymer has a repeating unit as shown in Formula (1) and is capped with a capping agent having a phenylethynyl group: wherein Ar is selected from one of the structures of the following Formulae (2) and (3): and n is an integer of between 3 and 8.
    Type: Application
    Filed: September 19, 2012
    Publication date: July 3, 2014
    Inventors: Wei Yan, Dan Wang
  • Patent number: 8758880
    Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (Ib) or (Ic) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: June 24, 2014
    Assignee: BASF SE
    Inventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jürg Kirner, Mathieu G. R. Turbiez
  • Publication number: 20140155625
    Abstract: A modified naturally-derived colorant comprising a naturally-derived colorant that is modified with an aliphatic quaternary ammonium salt, an aromatic quaternary ammonium salt, or a mixture or combination thereof. The modified naturally-derived colorant is compatible with phase change ink vehicles.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 5, 2014
    Applicant: XEROX CORPORATION
    Inventors: Mihaela Maria Birau, Salma Falah Toosi, C. Geoffrey Allen, Biby Esther Abraham, Peter G. Odell, Sandra J. Gardner
  • Publication number: 20130338208
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 19, 2013
    Applicants: U.S. GOVERNMANET AS REPRESENTED BY UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, EMORY UNIVERSITY
    Inventor: Jack L. Arbiser
  • Patent number: 8563595
    Abstract: The present invention includes compositions and methods for treating disorders of the skin or mucosa resulting from cancer therapies comprising: identifying a patient receiving cancer treatment; and administering to said patient an effective dose of a treated organic/inorganic complex material with an organic dye molecule or derivative thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: October 22, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventors: Russell R. Chianelli, Siddhartha Das
  • Publication number: 20120295948
    Abstract: The present invention relates to an indirubin-3?-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3?-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 22, 2012
    Applicant: ANYGEN CO., LTD.
    Inventors: Yong-Chul Kim, Jae-II Kim, Soo-Ho Ban, Soon-Young Jeong, Soo-Jeong Choi, Jung-Eun Lee
  • Publication number: 20110252507
    Abstract: The present invention relates generally to the use of plants as bioreactors for the production of molecules having useful properties such as inter alia polymers, metabolites, proteins, pharmaceuticals and nutraceuticals. More particularly, the present invention contemplates the use of grasses, and even more particularly C4 grasses, such as sugarcane, for the production of a range of compounds such as, for example, polyhydroxyalkanoates, pHBA, vanillin, indigo, adipic acid, 2-phenylethanol, 1,3-propanediol, sorbitol, fructan polymers and lactic acid as well as other products including, inter alia, other plastics, silks, carbohydrates, therapeutic and nutraceutic proteins and antibodies. The present invention further extends to transgenic plants and, in particular, transgenic C4 grass plants, capable of producing the compounds noted above and other products, and to methods for generating such plants.
    Type: Application
    Filed: July 13, 2010
    Publication date: October 13, 2011
    Applicants: The University of Queensland, BSES Limited
    Inventors: Stevens Michael Brumbley, Matthew Peter Purnell, Barrie Fong Chong, Lars Arved Petrasovits, Lars Keld Nielsen, Richard Bruce McQualter
  • Patent number: 8013174
    Abstract: Specific photochromic spirodihydrophenanthropyrans and their use in synthetic resin materials of all kinds, particularly for ophthalmic purposes. The compounds of the invention are photochromic pyran compounds derived from 9,10-dihydrophenanthrene in which at least one of the two carbon atoms at positions 9 and 10 belongs to a further ring system and thus forms a spiro linkage point.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: September 6, 2011
    Assignee: Rodenstock GmbH
    Inventors: Udo Weigand, Manfred Melzig, Yven Rohlfing
  • Publication number: 20100297405
    Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (1b) or (1c) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).
    Type: Application
    Filed: October 16, 2008
    Publication date: November 25, 2010
    Applicant: BASF SE
    Inventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jurg Kirner, Mathieu G.R. Turbiez
  • Publication number: 20100137356
    Abstract: A novel class of azaindole-indole coupled derivatives, their preparation methods, pharmaceutical compositions containing the same and the uses thereof. The common structural feature of these derivatives is that they are coupled by azaindole and indole bi-molecule at different positions, forming extended pi-conjugated systems. Such derivatives inhibited cell growth and proliferation by various mechanisms. The present compounds have improved solubility, increased bioavailability, and thus have enhanced drug actions, and reduced medical dosages and undesired responses.
    Type: Application
    Filed: June 6, 2008
    Publication date: June 3, 2010
    Inventors: Jingcai Cheng, Qizheng Yao, Zhaohui Wang, Weiyi Hua
  • Patent number: 7662973
    Abstract: Disclosed is a method for increasing the fluorescence of a Cyanine dye molecule comprising at least one NO2 group characterized by the reduction of the at least one NO2 group to NHOH or NH2 by the action of a nitroreductase. The cyanine dye molecule comprising at least one NO2 group can be used as a substrate for detecting nitroreductase enzyme activity in a composition and allows for the use of a nitroreductase enzyme in an enzyme-reporter system for the detection of analytes, binding reactions or gene expression.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: February 16, 2010
    Assignee: GE Healthcare UK Limited
    Inventors: Nicholas Thomas, Nigel Paul Michael, Valerie Millar, Beth Davies, Mark Samuel Jonathan Briggs
  • Patent number: 7572923
    Abstract: The present invention relates to an indirubin derivative having anticancer property by inhibiting cell proliferation as to human cancer cell line. More particularly, this invention provides the synthesis of indirubin derivative known as CDK(Cyclin-dependent kinase) inhibitor. Further, inhibition activity of proliferation as to human cancer cell line and apoptosis against induced-differentiation of said indirubin derivative are researched to develop a novel indirubin derivative having efficacious anticancer properties as to various human cell lines.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: August 11, 2009
    Assignee: Anygen Co., Ltd.
    Inventors: Yong-Chul Kim, Si Wouk Kim, Tae Sung Kim, Sang Kook Lee, Jae Il Kim, Jung-Hoon Yoon, Sang-Gun Ahn, Myoung Ju Moon
  • Publication number: 20090074825
    Abstract: The present invention includes methods, articles, compositions and colorant dyes and pigments that include biocidal N-halamine dye composition having two or more heterocyclic ring structures attached to one or more N-halamine groups, wherein one or more halogens associate with the one or more one or more N-halamine groups to affect biocidal activity.
    Type: Application
    Filed: September 19, 2008
    Publication date: March 19, 2009
    Applicant: Board of Regents, The University of Texas System
    Inventors: Yuyu Sun, Jie Luo
  • Patent number: 7429294
    Abstract: The present invention includes a paint or coating composition comprising an organic pigment or dye complexed to the surface of a layered or fibrous inorganic clay. A wide variety of paint colors can be obtained by varying the pH during the preparation as well as by varying the synthesis conditions and changing particle size of the clay. The paint has unprecedented stability.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 30, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Russell Chianelli, Lori A. Polette
  • Patent number: 7425235
    Abstract: The present invention includes a paint or coating composition comprising an organic pigment or dye complexed to the surface of a layered or fibrous inorganic clay. A wide variety of paint colors can be obtained by varying the pH during the preparation as well as by varying the synthesis conditions and changing particle size of the clay.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: September 16, 2008
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Russell Chianelli, Lori A. Polette
  • Patent number: 7309532
    Abstract: The present invention is related to a cyclopentaphenanthrene-based compound and an organic electroluminescence device using the same. In particular, the cyclopentaphenanthrene-based compound offers several advantages, including easy processibility, high solubility, superior color purity, color stability and thermal stability. Moreover, the cyclopentaphenanthrene-based compound may be used not only as a material for forming an organic layer of an organic electroluminescence device, particularly, a light-emitting layer, but also as a material of an organic pigment or nonlinear optical substance.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: December 18, 2007
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Kyu-Sik Kim, Byung-Hee Sohn, Lyong-Sun Pu, Jhun-Mo Son, Sang-Hoon Park, Ji-Hoon Lee, Woon-Jung Paek
  • Patent number: 7285663
    Abstract: The invention relates to a compound of general formula (I) in which C represents an alicyclic or heterocyclic group having C2v symmetry, and B represents ortho-C6-C18-arylene. The invention also relates to a method for producing this compound and to the use thereof as a coloring agent for coloring or pigmenting organic or inorganic high-molecular or low-molecular, particularly high-molecular, organic materials.
    Type: Grant
    Filed: December 13, 2003
    Date of Patent: October 23, 2007
    Assignee: Clariant Produkte (Deutschland) GmbH
    Inventors: Heino Heckmann, Hans Joachim Metz
  • Patent number: 7241897
    Abstract: This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: July 10, 2007
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Jannis G. Stavrianopoulos, Elazar Rabbam
  • Patent number: 7105562
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1–R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: September 12, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Cho Tang
  • Patent number: 7052541
    Abstract: The present invention includes a paint or coating composition comprising an organic pigment or dye complexed to the surface of a layered or fibrous inorganic clay. A wide variety of paint colors can be obtained by varying the pH during the preparation as well as by varying the synthesis conditions and changing particle size of the clay. The paint has unprecedented stability.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: May 30, 2006
    Assignee: Board of Regents, The University of Texas System
    Inventors: Russell Chianelli, Lori A. Polette
  • Patent number: 6987092
    Abstract: The present invention relates to novel indigoid binsindole derivatives which can be used for the manufacture of a medicament for the treatment of solid cancers.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: January 17, 2006
    Assignee: Faustus Forschungs Cie. Translational Cancer Research GmbH
    Inventors: Gerhard Eisenbrand, Doris Marko, Andrea Thommet, Stefan Schwahn
  • Patent number: 6933315
    Abstract: A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: August 23, 2005
    Inventors: Longgui Wang, Xiaomei Liu, Ruihuan Chen
  • Publication number: 20040225002
    Abstract: A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 11, 2004
    Inventors: Longgui Wang, Xiaomei Liu, Ruihuan Chen
  • Publication number: 20040138436
    Abstract: The present invention relates to colorant of the general formula, wherein A, B and B′, m and m′ and n and n′ are as defined in the description. The colorants can be used for the pigmenting of porous materials and in injekt printing and, in the case of pigmenting, are converted to the insoluble pigment form. In the pigmenting of porous materials, for example in the pigmenting of wood or anodised aluminium in the pores, the colorants yield very good penetration and fastness to light and, in injekt printing, yield very good water-resistance.
    Type: Application
    Filed: October 16, 2003
    Publication date: July 15, 2004
    Inventors: Hans-Thomas Schacht, Gilbert Moegle
  • Publication number: 20040024010
    Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: March 10, 2003
    Publication date: February 5, 2004
    Applicant: Sugen, Inc.
    Inventors: Pen Cho Tang, Li Sun, Todd Anthony Miller, Congxin Liang, Ngoc My Tran, Anh Thi Nguyen, Asaad Nematalla
  • Publication number: 20030164118
    Abstract: Organic pigments are conditioned by introducing a liquid prepigment suspension into a miniaturized continuous reactor and thermally treating therein.
    Type: Application
    Filed: March 31, 2003
    Publication date: September 4, 2003
    Applicant: Clariant Finance (BVI) Limited
    Inventors: Uwe Nickel, Klaus Kund, Erwin Dietz, Joachim Webber, Olaf Schupp
  • Patent number: 6562121
    Abstract: Organic pigments are conditioned by introducing a liquid prepigment suspension into a miniaturized continuous reactor and thermally treating therein.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: May 13, 2003
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Uwe Nickel, Klaus Kund, Erwin Dietz, Joachim Weber, Olaf Schupp
  • Publication number: 20020107404
    Abstract: Sulfanyl-indirubin derivatives, their production and their intermediate products for production, as well as their use as medications for treating cancer, such as solid tumors and leukemia; auto-immune diseases, such as psoriasis, alopecia and multiple sclerosis, chemotherapy agent-induced alopecia and mucositis; cardiovascular diseases, such as stenoses, arterioscleroses and restenoses; infectious diseases, such as, e.g., those caused by unicellular parasites, such as trypanosoma, toxoplasma or plasmodium, or those caused by fungi; nephrological diseases, such as, e.g., glomerulonephritis; chronic neurodegenerative diseases, such as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases, such as ischemias of the brain and neurotraumas; viral infections, such as, e.g., cytomegalic infections, herpes, hepatitis, B and C, and HIV diseases, are described.
    Type: Application
    Filed: October 24, 2001
    Publication date: August 8, 2002
    Applicant: Schering AG
    Inventors: Olaf Prien, Andreas Steinmeyer, Gerhard Siemeister, Rolf Jautelat
  • Patent number: 6359122
    Abstract: The invention relates to the preparation of pyrocarbonic acid diesters by an improved process and to the novel pyrocarbonic acid diesters prepared according to said process as well as to the use thereof. The core of the invention is a process for the preparation of a pyrocarbonic acid diester of formula (I) wherein R1 and R1′ are each independently of the other branched or straight-chain C1-C24alkyl, C3-C24alkenyl, C3-C24alkynyl, C4-C12cycloalkyl, C4-C12cycloalkenyl or C7-C24aralkyl, each of which is unsubstituted or substituted by one or more than one substituent which is inert under the reaction conditions, by reacting at least one ester carbonate of formula (II)  with 40-50 mol % of a sulfochloride of formula (IV)  in the presence of 0.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: March 19, 2002
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: John Zambounis, Véronique Hall-Goulle
  • Patent number: 6150533
    Abstract: Compounds effective in treating disorders of the serotonin-affected neurological systems are provided, such compounds having the following formula: ##STR1## wherein: R.sub.1 is hydrogen, lower alkyl, phenyl, or substituted phenyl;X and Y together complete a lactam, imidazole, imidazolone, or thioimidazolone ring;Z is hydrogen, halogen, or lower alkoxy;W is hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or a trifluoromethyl group;and n=2 to 5; or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: November 21, 2000
    Assignee: American Home Products Corp.
    Inventors: Richard E. Mewshaw, James A. Nelson
  • Patent number: 6127549
    Abstract: Compounds of formula:A(B).sub.x, (I),wherein x is an integer from 1 to 4,A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, isoindolinone, isoindoline, dioxazine, phthalocyanine or azo series, which radical contains x N-atoms attached to B, preferably with at least one directly adjacent or conjugated carbonyl group,B is a group of formula: ##STR1## and, if x is 2, 3 or 4, may also be one, two or three hydrogen atoms. The symbols Q, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y, Z, m und n, are as defined in claim 1.These carbamate group-containing soluble chromophores are distinguished by outstanding solid state fluorescence in the UV range as well as the by ease with which they can be converted to the corresponding pigments in the substrate in which they are incorporated.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: October 3, 2000
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Zhimin Hao, John S. Zambounis, Abul Iqbal
  • Patent number: 6063924
    Abstract: Compounds of formulaA(B).sub.x (I),wherein x is an integer from 1 to 4,A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, isoindolinone, isoindoline, dioxazine, phthalocyanine, diketopyrrolopyrrole or azo series, which radical A contains x N-atoms linked with B, preferably with at least one immediately adjacent or conjugated carbonyl group.B is a group of formula ##STR1## and, if x=2, 3 or 4, can also be one, two or three hydrogen atom(s), and wherein Q is a group of formula ##STR2## These soluble chromophores can be readily converted to the corresponding pigments by heating, even in the substrate into which they can be incorporated without any difficulty in dissolved form.R.sub.1 -R.sub.9 are as defined herein.
    Type: Grant
    Filed: July 22, 1996
    Date of Patent: May 16, 2000
    Assignee: Ciba Specialty Chemicals Corporation
    Inventor: Veronique Hall-Goulle
  • Patent number: 5886160
    Abstract: Compounds of formulaA(B).sub.x, (I),wherein x is an integer from 1 to 4,A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, isoindolinone, isoindoline, dioxazine, phthalocyanine or azo series, which radical contains x N-atoms attached to B, preferably with at least one directly adjacent or conjugated carbonyl group,B is a group of formula ##STR1## and, if x is 2, 3 or 4, may also be one, two or three hydrogen atoms. The symbols Q, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y, Z, m and n, are as defined in claim 1.These carbamate group-containing soluble chromophores are distinguished by outstanding solid state fluorescence in the UV range as well as the by ease with which they can be converted to the corresponding pigments in the substrate in which they are incorporated.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: March 23, 1999
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Zhimin Hao, John S. Zambounis, Abul Iqbal
  • Patent number: 5755875
    Abstract: Compounds selected from the series consisting of the perylenecarboximide, quinacridone, isoindoline, indigoid, azo, benzodipyrrolone, benzodifuranone, furanofuran, pyrrolo?2,5-b!pyrrole and bianthraquinone chromophores containing at least one grouping of formula ##STR1## wherein each A may be N--CN or O, with the proviso that at least one A must be N--CN, X is --N(R)--, --O-- or --S--, R is hydrogen, C.sub.1 -C.sub.18 alkyl, unsubstituted or halogen- or C.sub.1 -C.sub.4 alkyl-substituted phenyl, benzyl or phenethyl, and m and n are each independently of the other 0 or 1.Depending on the nature of their substituents, these compounds can be used as polymer-soluble dyes or as pigments for coloring high molecular weight organic material. They are distinguished by a surprisingly high solid-state fluorescence.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: May 26, 1998
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: John S. Zambounis, Zhimin Hao, Abul Iqbal
  • Patent number: 5686625
    Abstract: Process for the preparation of an N-substituted glycine ester or an N-substituted glycine acid by reaction of a glyoxylic acid ester half-acetal (hemiacetal) or glyoxylic acid half-acetal (hemiacetal) with an amine and hydrogenation of the intermediate product formed by this reaction, and the use of the process in a process for the preparation of indoxyl and indigo derivatives by cyclization of an N-arylglycine ester, prepared by the above process, in a molten alkali metal carbonate or alkaline earth metal carbonate with or without addition of an alkali metal amide, and if appropriate oxidation of the indoxyl derivative formed by this reaction to give the corresponding indigo derivative.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: November 11, 1997
    Assignee: DSM Chemie Linz GmbH
    Inventor: Carlo Kos
  • Patent number: 5667764
    Abstract: Compounds are provided having the capability of binding therapeutically active substances to lipid containing bio-compatible particles, such as cells or viruses. These compounds include a bio-affecting moiety, comprising a therapeutically active substance, which is linked via a linking moiety to at least one hydrocarbon substituent selected so that the compounds is sufficiently non-polar to impart lipid binding capability to the compound. Thus, compounds of the invention are useful for site-selective delivery of therapeutic agents, and retention thereof at the selected site.Methods are provided for using various compounds of the invention in treatment of diseases or other pathological conditions. For example, methods are provided for treatment of: (1) post-angioplasty restenosis; (2) rheumatoid arthritis; (3) tumor cell proliferation, particularly tumor cells associated with ovarian cancer; and (4) psoriasis.
    Type: Grant
    Filed: May 15, 1992
    Date of Patent: September 16, 1997
    Assignee: Zynaxis, Inc.
    Inventors: Gregory A. Kopia, Paul K. Horan, Brian D. Gray, David E. Troutner, Katharine A. Muirhead, Kamleshkumar A. Sheth, Chia-En Lin, Zhizhou Yu, Bruce D. Jensen, Sue Ellen Slezak
  • Patent number: 5637708
    Abstract: Agents having the structure,U--CH.sub.2 --V--CH.sub.2 --W,and agents having the structure,U--CH.sub.2 --V--CH.sub.2 --W--X--Y--Z,where U, W, and Z are double fused aromatic rings, V is a single six-membered aromatic ring with a hydroxyl group constituent, X is a polar group, and Y is a positively charged group, are disclosed. The double fused aromatic rings can be a five-membered aromatic ring, or a six-membered aromatic ring, fused to a six-membered aromatic ring; the double fused aromatic rings can comprise heteroatoms. The agents can be used as capsid stabilizing or antiviral agents.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 10, 1997
    Assignee: President and Fellows of Harvard College
    Inventors: James M. Hogle, Martin Karplus, Diane Joseph-McCarthy
  • Patent number: 5536842
    Abstract: A process for purifying indigo comprises extracting an aqueous leuco indigo alkali metal salt solution with an inert solvent under oxygen-excluding conditions and conventionally regenerating the indigo by oxidation.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: July 16, 1996
    Assignee: BASF Aktiengesellschaft
    Inventors: Udo Bergmann, Manfred Gang, Reinhold Kohlhaupt
  • Patent number: 5502061
    Abstract: The present invention provides HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: March 26, 1996
    Assignee: Eli Lilly and Company
    Inventors: Kwan Y. Hui, Charles D. Jones, Louis N. Jungheim, Pamela A. Pennington
  • Patent number: 5444495
    Abstract: A MUSE-NTSC converter of a relatively simple and small scale circuit design. An oscillation signal from a 28.63636 MHz oscillator (20) is eight times as large as a subcarrier frequency fsc. A Y image processing circuit (17) and a chroma encoder (18) can perform various kinds of processing, such as dividing a frequency of the oscillation signal from the 28.63636 MHz oscillator (20) and the like, to produce a subcarrier frequency. A signal separating circuit (3') receives the oscillation signal from the 28.63636 MHz oscillator (20) as a single system clock and performs some kinds of signal processing which vary from a full wide mode to a zoom mode. Thus, in performing PLL on system clocks in the MUSE mode and the NTSC mode, there may be only one PLL circuit (21) for synchronizing an oscillation signal from a 32.4 MHz oscillator (19) and the oscillation signal from the 28.63636 MHz oscillator (20) in phase.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: August 22, 1995
    Assignee: Mitsubishi Denki Kabushiki Kaisha
    Inventors: Akiko Takahama, Masahiko Nakamura, Hiroyuki Nakayama, Eiji Arita, Yoichi Asamoto
  • Patent number: 5424453
    Abstract: This invention relates to a process for the purification of indigo, wherein the indigo is heated in an inert organic solvent at from 150.degree. to 250.degree. C. and preferably from 180.degree. to 220.degree. C.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: June 13, 1995
    Assignee: BASF Aktiengesellschaft
    Inventors: Reinhold Kohlhaupt, Udo Bergmann
  • Patent number: 5403851
    Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e.g., sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e.g., jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e.g., contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6. ophthalmological diseases; 7. animal breeding (e.g., regulation of fertility, puberty, pelage color).
    Type: Grant
    Filed: April 5, 1994
    Date of Patent: April 4, 1995
    Assignee: Interneuron Pharmaceuticals, Inc.
    Inventors: Kay J. D'Orlando, Kenneth W. Locke, Emile M. Bellott, Richard L. Gabriel, Michael D. Nohrden, Yesh P. Sachdeva, Salah A. Zahr, Emile Al-Farhan, Subramaniam Krishnananthan
  • Patent number: 5264032
    Abstract: Pigment preparation essentially comprisinga) at least one pigment from the class of azo, anthrapyrimidine, anthanthrone, quinacridone, perinone, diketopyrrolopyrrole, dioxazine, flavanthrone, indanthrone, isoindolinone, isoviolanthrone, perylene, phthalocyanine, pyranthrone or thioindigo pigments or a mixture of pigments belonging to various classes, andb) at least one dispersant of the formula (I) ##STR1## in which P, independently of the pigments mentioned in a), is a radical of an anthanthrone azo, quinacridone, perinone, diketopyrrolopyrrole, dioxazine, indanthrone, perylene, phthalocyanine or thioindigo pigment,R.sup.1 and R.sup.2, independently of one another, are hydrogen, halogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.
    Type: Grant
    Filed: October 21, 1992
    Date of Patent: November 23, 1993
    Assignee: Hoechst AG
    Inventors: Erwin Dietz, Manfred Urban
  • Patent number: 5187283
    Abstract: An indigo compound is prepared from a corresponding indole compound which is unsubstituted at the 2- and 3- positions. The indole compound and an organic hydroperoxide are reacted in the presence of a catalyst which is a metal selected from the group consisting of the metals of Groups 4, 5 and 6 of the periodic table or a compound of the metal. The reaction is conducted while taking out water from a reaction system, said water being that introduced in the reaction system or formed during the reaction, or while controlling the amount of water, which is introduced in the reaction system, at a level not greater than 1 mole per mole of the indole compound.
    Type: Grant
    Filed: November 21, 1991
    Date of Patent: February 16, 1993
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Yoshihiro Yamamoto, Usaji Takaki, Shinobu Aoki, Yoshihisa Inoue, Isao Hara